113 related articles for article (PubMed ID: 19536865)
1. Promising tumor-associated antigens for future prostate cancer therapy.
Li Y; Cozzi PJ; Russell PJ
Med Res Rev; 2010 Jan; 30(1):67-101. PubMed ID: 19536865
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis as a strategic target for prostate cancer therapy.
Li Y; Cozzi PJ
Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
[TBL] [Abstract][Full Text] [Related]
3. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
4. Targeting uPA/uPAR in prostate cancer.
Li Y; Cozzi PJ
Cancer Treat Rev; 2007 Oct; 33(6):521-7. PubMed ID: 17658220
[TBL] [Abstract][Full Text] [Related]
5. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
6. The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression.
Madigan MC; Kingsley EA; Cozzi PJ; Delprado WJ; Russell PJ; Li Y
Cancer Immunol Immunother; 2008 Sep; 57(9):1367-79. PubMed ID: 18273614
[TBL] [Abstract][Full Text] [Related]
7. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates.
Li Y; Abbas Rizvi SM; Blair nee Brown JM; Cozzi PJ; Qu CF; Ow KT; Tam PN; Perkins AC; Russell PJ; Allen BJ
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):896-908. PubMed ID: 15465208
[TBL] [Abstract][Full Text] [Related]
8. Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates.
Wang J; Abbas Rizvi SM; Madigan MC; Cozzi PJ; Power CA; Qu CF; Morgenstern A; Apostolidis C; Russell PJ; Allen BJ; Li Y
Prostate; 2006 Dec; 66(16):1753-67. PubMed ID: 16955401
[TBL] [Abstract][Full Text] [Related]
9. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.
Cozzi PJ; Wang J; Delprado W; Madigan MC; Fairy S; Russell PJ; Li Y
Hum Pathol; 2006 Nov; 37(11):1442-51. PubMed ID: 16949925
[TBL] [Abstract][Full Text] [Related]
11. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
13. New prospectives of prostate cancer gene therapy: molecular targets and animal models.
Hsieh CL; Chung LW
Crit Rev Eukaryot Gene Expr; 2001; 11(1-3):77-120. PubMed ID: 11693967
[TBL] [Abstract][Full Text] [Related]
14. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer.
Han KR; Seligson DB; Liu X; Horvath S; Shintaku PI; Thomas GV; Said JW; Reiter RE
J Urol; 2004 Mar; 171(3):1117-21. PubMed ID: 14767283
[TBL] [Abstract][Full Text] [Related]
15. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
Stege R; Grande M; Carlström K; Tribukait B; Pousette A
Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
[TBL] [Abstract][Full Text] [Related]
17. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA).
Hall CL; Tsan R; Mugnai G; Mazar A; Radinsky R; Pettaway CA
Prostate; 2004 May; 59(2):167-76. PubMed ID: 15042617
[TBL] [Abstract][Full Text] [Related]
18. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
19. Metastases of prostate cancer express estrogen receptor-beta.
Lai JS; Brown LG; True LD; Hawley SJ; Etzioni RB; Higano CS; Ho SM; Vessella RL; Corey E
Urology; 2004 Oct; 64(4):814-20. PubMed ID: 15491740
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease.
Donovan MJ; Osman I; Khan FM; Vengrenyuk Y; Capodieci P; Koscuiszka M; Anand A; Cordon-Cardo C; Costa J; Scher HI
BJU Int; 2010 Feb; 105(4):462-7. PubMed ID: 19624594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]